Literature DB >> 17368038

ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance.

Susan D P W M de Jonge-Peeters1, Folkert Kuipers, Elisabeth G E de Vries, Edo Vellenga.   

Abstract

ATP-binding cassette (ABC) transporters are known to play an important role in human physiology, toxicology, pharmacology, and numerous disorders including acute myeloid leukemia (AML). In AML only a few cells have properties allowing for ongoing proliferation and for expansion of this malignant disorder. These very primitive cells, referred to as leukemic stem cells, reside mostly in a quiescent cell cycle state. These cells have the capacity of self-renewal and are likely characterized by a high expression of a number of ABC transporters. In addition, over-expression of certain ABC transporters in leukemic cells has been associated with poor treatment outcome in AML patients. Therefore, to be able to improve diagnostics and therapies for AML patients, it may be important to better characterize this quiescent stem cell population. Particularly knowledge of the biology of highly expressed ABC transporters in these primitive leukemic cells might provide new insights to improve therapeutic options. This review provides an overview about ABC transporters and AML in general and particularly of the ABC transporters involved in multidrug resistance and cholesterol metabolism in primitive normal and leukemic cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368038     DOI: 10.1016/j.critrevonc.2007.02.003

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  36 in total

1.  Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Authors:  Steven M Kornblau; Mark D Minden; David B Rosen; Santosh Putta; Aileen Cohen; Todd Covey; David C Spellmeyer; Wendy J Fantl; Urte Gayko; Alessandra Cesano
Journal:  Clin Cancer Res       Date:  2010-06-04       Impact factor: 12.531

Review 2.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

Review 3.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

4.  Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy.

Authors:  Mario Tiribelli; Dora Fabbro; Alessandra Franzoni; Renato Fanin; Giuseppe Damante; Daniela Damiani
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

5.  Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia.

Authors:  Xavier Thomas
Journal:  World J Stem Cells       Date:  2009-12-31       Impact factor: 5.326

6.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

7.  Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells.

Authors:  Leilei Tang; Saskia M Bergevoet; Christian Gilissen; Theo de Witte; Joop H Jansen; Bert A van der Reijden; Reinier A P Raymakers
Journal:  BMC Pharmacol       Date:  2010-09-13

8.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

9.  ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.

Authors:  Lijun Ma; Ting Liu; Yiran Jin; Jun Wei; Yinxue Yang; Hongquan Zhang
Journal:  Tumour Biol       Date:  2016-07-23

Review 10.  Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.

Authors:  M Mimeault; S K Batra
Journal:  Panminerva Med       Date:  2008-03       Impact factor: 5.197

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.